Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.